SCHEMBL5017735

SCHEMBL5017735

CN(C)CC(=O)Nc1cc(-c2ccccn2)nc(-c2cccs2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 9/20 0.68
ADORA1 P30542 7/20 0.68
ADORA3 P0DMS8 3/20 0.60
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ESR1 P03372 1/20 0.41
POLB P06746 1/20 0.41
STAT3 P40763 1/20 0.41
ESR2 Q92731 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017711 0.93 ADORA2A (0.59) ADORA2AADORA1ADORA3MAPTSMN1; SMN2
SCHEMBL5017774 0.89 ADORA2A (0.75) ADORA2AADORA1ADORA3MAPTSMN1; SMN2
SCHEMBL5022856 0.87 ADORA2A (0.50) ADORA2AADORA1ADORA3TUBB4ATUBB
SCHEMBL5022278 0.86 ADORA2A (0.69) ADORA2AADORA1ADORA3SMN1; SMN2ESR1
SCHEMBL1489618 0.86 ADORA2A (0.69) ADORA2AADORA1ADORA3SMN1; SMN2ESR1
SCHEMBL5026314 0.85 ADORA2A (0.60) ADORA2AADORA1ADORA3
SCHEMBL5026255 0.85 ADORA2A (0.57) ADORA2AADORA1ADORA3MAPTPOLB
SCHEMBL1489659 0.84 ADORA2A (0.71) ADORA2AADORA1ADORA3POLBALDH1A1
SCHEMBL5025057 0.82 ADORA2A (0.58) ADORA2AADORA1ADORA3
SCHEMBL1489615 0.81 ADORA2A (1.00) ADORA2AADORA1ADORA3ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.